Formulary guidance and transparency from P&T to point of care

Bronwyn Mixter

Recent Posts

Trends That Matter for Bipolar Disorder Medications

Posted by Bronwyn Mixter on Apr 23, 2020

A recently approved brand drug for bipolar disorder will have little impact on how health plans cover these medications, experts tell AIS Health. Health plans will continue to encourage the use of less expensive generic bipolar drugs.

The brand drug, Allergan plc's Vraylar (cariprazine), was approved by the FDA to treat depressive episodes associated with bipolar 1 disorder in adults. It is an oral, once-daily atypical antipsychotic.
Read More

Topics: Industry Trends, Market Access, Data & Analytics